Treatment of Kaposis Sarcoma

Abstract

Kaposi’s sarcoma (KS) is the most common malignancy associated with human immunodeficiency virus-1 (HIV) infection.’ During the early years of the acquired immunodeficiency syndrome (AIDS) epidemic, KS was the presenting manifestation of AIDS in 10%-15% of HIV-infected homosexual men and 1%-2% of HIV-infected individuals from other risk categories.2Over the past decade, the proportion of individuals presenting with KS as their AID S-defining illness has declined. Data from the Multicenter AIDS Cohort Study (MACS), an observational study of homosexual and bisexual men, demonstrate an increase in the incidence of KS as an AIDS-defining event in the early 1990s followed by a decline in incidence in 1996-1997.3KS as a secondary AIDS diagnosis rose from 23% in the mid-1980s, to 42% in the early 1990s, to 50% in 1996-1997.3In recent years, the overall incidence of KS has decreased. A population based cancer surveillance study in Washington state observed a decrease in the average number of KS cases from 118 between 1990 and 1995 to 76 in 1996 and 21 in 1997.4 KeywordsLiposomal DoxorubicinMulticenter AIDS Cohort StudyLiposomal DaunorubicinLiposomal AnthracyclinesThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.